Navigation Links
AstraZeneca's David Brennan Elected PhRMA Board Chairman
Date:4/3/2009

SAN ANTONIO, April 3 /PRNewswire/ -- AstraZeneca Chief Executive Officer David Brennan was elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the group's annual meeting.

In a speech to the meeting attendees, Brennan called on his industry colleagues and all segments of the health care system to work together in a new collaborative and bipartisan manner on meaningful health care reform that includes:

  • Increased access to health and prescription drug coverage for the uninsured and the under-insured.
  • Greater emphasis on disease prevention to reduce the burden of chronic diseases on individuals and the health care system as a whole.
  • Reduced co-pays for prescription medicines to bring them more in line with what patients pay for other health services.
  • Ensuring the Food and Drug Administration has the funding it needs to protect patients by effectively reviewing life-saving and enhancing medications.

Brennan said a modernized health system should also protect intellectual property and promote innovation as scientists seek cures to the world's deadliest and most debilitating illnesses.

"The pharmaceutical industry is uniquely poised to be both a source of innovative medicines and a trusted member of the health care community," Brennan said. "Pharmaceutical researchers and manufacturers can play a critical role in advancing health solutions that build on the strengths of the U.S. health care system and address its weaknesses.

"I look forward to working with my industry colleagues, policymakers, health advocacy organizations and new, nontraditional partners to promote policies that expand access to affordable health coverage, address the burden of chronic disease and close the gaps in health care quality while fostering continued innovation," Brennan said.

Brennan, who will serve as PhRMA chairman for a year, has been AstraZeneca's chief executive officer since Jan. 1, 2006. Under Brennan's leadership, AstraZeneca made a number of changes that tie directly to its mission of making a difference to patient health, including:

  • Expanding its prescription savings programs in the United States so that an uninsured family of four earning up to $60,000 per year may qualify to receive their AstraZeneca medicines for free.
  • Introducing a prescription savings program specifically for people with Medicare Part D, through which a senior couple earning up to $40,000 per year may qualify for significant savings.
  • Becoming the first company to include information about its prescription savings programs in product advertisements, and supporting FDA review of these ads.
  • Supporting disease prevention and employee wellness through sponsorship of the American Heart Association START! Program and the National Senior Games Association, and being one of the first companies to receive "CEO Cancer Gold Standard" accreditation by the CEO Roundtable on Cancer.
  • Becoming the first company to give nationwide, large-scale support to the American Cancer Society's Patient Navigator Program, which will link cancer patients at more than 50 sites across the U.S. with individuals who serve as their personal guides through various aspects of their cancer experience.
  • Supporting the National Alliance on Mental Illness's Connection Recover Support Group, which plans to provide a support group within reasonable traveling distance for every American who lives with mental illness, every day of the week, in English or Spanish, by the year 2010.
  • Becoming a founding member of the Alliance for a Stronger FDA, a coalition of organizations and individuals who support increased Congressional funding for FDA.

From 2001 until his appointment to global CEO, Brennan was president and chief executive officer of AstraZeneca LP, the Company's North America subsidiary. He was appointed Executive Board Director of AstraZeneca in 2005, with responsibility for the United States, the company's largest market, as well as all North American operations.

David began his career in 1975 at Merck, where he rose from sales representative in the U.S. division to general manager of Chibret International, a French subsidiary of Merck specializing in ophthalmics. He joined AstraMerck in 1992 with responsibility for helping to build the joint venture into a multi-billion dollar business in the United States.

Prior to the AstraZeneca merger he was responsible for business planning and development at Astra Pharmaceuticals. He was appointed senior vice president of commercial operations of AstraZeneca Pharmaceuticals LP in 1999. Brennan is an alumnus of Gettysburg College.

PhRMA represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier and more productive lives.

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business.

For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.


'/>"/>
SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Norman E. Rosenthal Joins Paul McCartney and David Lynch at Press Conference for Benefit Concert
2. eHealth Initiative Applauds Appointment of David Blumenthal as New National Coordinator for Health Information Technology
3. Dr. Barry Friedberg comments on David vs. Goliath: Whos Really in the Pursuit of Patient Safety & Satisfaction?
4. Media Advisory: Medco CEO David B. Snow Jr. To Address American Enterprise Institute: Health IT: Empowering Precision Medicine
5. David Teuscher, MD, Elected Secretary of Academy Board of Councilors
6. Veteran Rehab Specialist, David Glancy, Joins Fast-Growing Alliance Seating & Mobility in Michigan
7. Paul McCartney to Headline Benefit Concert for David Lynch Foundation at Radio City Music Hall on Saturday, April 4
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center First in Nation to Use NaviStar(R) RMT ThermoCool(R) Catheter Since Technology Received FDA Approval
9. David W. Polly Jr., MD, Elected Secretary of Academy Board of Specialty Societies
10. The Chopra Center Introduces Mind-body Health Programs for Spanish Speakers: Chopra en Espanol Connects Spanish Speakers Worldwide to Deepak Chopra and David Simons Global Message of Wellness
11. World-Renowned Golf Instructor David Leadbetter Promotes VaNu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Today Omega Institute, a leading destination ... innovative workshops and training opportunities in the growing field of yoga therapy ... who are dealing with specific health issues—including injuries, illnesses, and temporary or chronic health ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Global Wellness Summit (GWS) today announced that ... offerings of Europe, a continent that pioneered the medical/wellness concept for the world. , ... in medical wellness, including Henri Chenot, Founder of the Chenot Group, which operates wellness ...
(Date:5/25/2016)... Harrisburg, PA (PRWEB) , ... May 25, 2016 ... ... today announced the results of its annual Medical and Prescription Drug survey ... health benefits. , The survey, which was conducted in December 2015, indicates ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & ... turn back the hands of time of female aging. The Juliet™ ... Women with symptoms such as leakage, laxity, itchiness and pain have reported real relief ...
(Date:5/25/2016)... ... 25, 2016 , ... Consumer access to organic foods and grower access to ... of whole grain cereals and other plant-based foods, will introduce the first consumer product ... wheat processed by Hesco/Dakota Organic Products. , The transitional designation means the cereal was ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
(Date:5/23/2016)... , May 23, 2016 ... Market Size, Share, Development, Growth and Demand Forecast ... Single and Other), by Application (Drug Discovery and ... End Users (Pharmaceuticals, Life Science and Biotechnology, Academic ... P&S Market Research, the global mass spectrometry ...
Breaking Medicine Technology: